SOMAÍ Pharmaceuticals

Who are we? SOMAÍ Pharmaceuticals is a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio. SOMAÍ owns a state-of-the-art manufacturing facility and indoor cultivation in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets. In this video, Michael Sassano, Founder and Interim CEO of SOMAÍ, and Rita Barata, Chief Marketing Officer, take CannaReporter on a tour of SOMAÍ's state-of-the-art facilities in Portugal, explaining SOMAÍ story, values, and future projects for the company. This video is an advertising mini-doc and was made by the CannaReporter® Commercial and Marketing department. #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

We're thrilled to announce the appointment of Lauren Stark as General Manager for SOMAÍ Pharmaceuticals in Australia. With over 25 years of leadership experience in health, pharmacy, and real estate, Lauren is a results-driven powerhouse known for building high-performing teams and launching brands into competitive markets. Her passion for advancing healthcare aligns perfectly with SOMAÍ’s mission, and her expertise in the Medicinal Cannabis sector promises exciting growth for our team and patients alike. Join us in welcoming Lauren to SOMAÍ! If you want to learn more, please visit SOMAÍ Australia: https://lnkd.in/dFgFPuXy #NewBeginnings #SOMAÍ #FemaleLeadership #CannabisIndustry #HealthcareInnovation #NaturalMedicine #WellnessJourney #TeamSOMAÍ

The growth of the German medical cannabis market is poised to be highly profitable for the country. One billion euros of sales with a taxable 19% VAT would produce an additional 190 million euros in taxes, not to mention the additional jobs the medical cannabis market would create. There isn't a politician in the European Union who can ignore the positive impact of these taxes and increased citizen safety through regulation. In fact, most lawmakers are pushing ahead toward more access in their own countries. Big pharma distributors and telemedicine providers are paying attention to those numbers, too. Read the latest article by Michael Sassano published in krautinvest.de: https://lnkd.in/dcfH4adA #germancannabismarket

Poland is the fastest-growing new cannabis market in the entire global medical space. Not only is the extracts market growing at more than 30% CAGR, but the country’s recent increase in importation limits further reinforces the expected market growth potential. Most cannabis companies overlook Poland because of the difficulties in registering products at a more onerous level than in other high-growth countries like Germany. However, two companies, Cosma S.A. and SOMAÍ Pharmaceuticals, are changing the face of cannabis in Poland together. Read the full text by clicking on the picture below. #medicalcannabisinpoland #Cosma #SOMAÍ

SOMAÍ Pharmaceuticals, in collaboration with Universidade Lusófona - Centro Universitário Lisboa (UL), proudly announces the publication of their joint research, "The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review," in the prestigious journal Pharmaceuticals - MDPI. “At SOMAÍ, science is at the heart of all our product ranges,” said Michael Sassano, CEO of SOMAÍ Pharmaceuticals. “SOMAÍ publishes its minor cannabinoids as well as terpenes and prides itself on the biggest range of specialized proprietary terpene formulations. Essentials, Origins, and Senses lines are the cornerstone of our approach to terpenes. This research underscores our dedication to unlocking the full potential of minor cannabinoids and terpenes, paving the way for more innovative solutions in medicinal cannabis.” SOMAÍ Pharmaceuticals continues to work alongside UL to drive this essential research forward, bringing reliable and consistent medicinal cannabis products to patients while expanding scientific knowledge. “At Universidade Lusófona, we are thrilled to partner with SOMAÍ Pharmaceuticals, a true leader in the medicinal cannabis field. This collaboration marks an exciting step forward in unlocking the potential of terpenes and their role in enhancing therapeutic outcomes. Working with SOMAÍ’s innovative team and cutting-edge technologies inspires us to push the boundaries of research and deliver impactful findings. Together, we are shaping the future of cannabis-based medicine, and we couldn’t be prouder to be part of this journey,” said Dr Maria Costa, Professor at Lusófona University. Read the full news here: https://lnkd.in/dVkb6JwM #CannabisResearch #EntourageEffect #Terpenes #CannabisScience #SOMAÍPharmaceuticals #UniversidadeLusófona #CollaborativeResearch

We are #hiring for a new Propagation Lead position in Sintra, Lisbon. Apply today or share this information with your network.

We are delighted to announce that our Board Member and Managing Director, Anton Nakhodkin, has been featured in the October/November edition of Forbes Portugal. At SOMAÍ, we take immense pride in our team of visionary leaders, whose expertise continues to earn recognition on national and global stages. This acknowledgment underscores our steadfast commitment to fostering strong, collaborative relationships with our partners and stakeholders as we work together toward shared success. For media enquiries, please email us at hello@somaipharma.eu #Leadership #Innovation #VentureCapital #Entrepreneurship #ForbesPT #TeamExcellence

Today marks the beginning of the 2024 edition of the Order of Pharmacists Congress with the theme "More Innovation, More Health." As innovation is also one of SOMAÍ’s core values, the company could not miss the opportunity to participate. SOMAÍ is presenting two posters: - SOMAÍ Paradigm: Leading Innovation in Medical Cannabis; - Ensuring Cannabis Product Integrity: Genetic Evaluation Using SSR Markers. These posters were developed by our internal R&D team in collaboration with Universidade Lusófona - Centro Universitário Lisboa. #SOMAÍ #medicalcannabis #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews

SOMAÍ Pharmaceuticals and Releaf have joined forces to enhance the patient experience in the U.K. medicinal cannabis market. This collaboration combines SOMAÍ’s unmatched portfolio of EU-GMP-certified extracts and premium flower with Releaf’s innovative health tech platform, ensuring consistent access to high-quality, patient-first solutions. Together, we’re addressing market challenges like supply chain issues and limited patient choice, setting a new standard for transparency and independence in cannabis care. With this partnership, we’re not just meeting patient needs—we’re redefining what’s possible in the U.K. cannabis market. Click on the article to learn more about how this partnership is transforming patient experiences. #CannabisCare #MedicinalCannabis #CannabisInnovation #PatientFirst #SOMAÍPharmaceuticals #Releaf

Estamos #contratando para um novo cargo de Artwork Specialist. Candidate-se hoje mesmo ou compartilhe este anúncio com sua rede. We are hiring an Artwork Specialist, please apply or share with your network.